---
date: '2026-01-30T19:15:10+00:00'
draft: false
image: https://res.cloudinary.com/dg7khxdal/image/upload/v1769802653/evofutura/uploads/2026/01/tesla-meta-microsoft-power-metallic-mines-lulu.jpg
image_credit: 'Source: Proactiveinvestors NA'
source_name: Proactiveinvestors NA
source_url: https://www.proactiveinvestors.com/companies/news/1086599/tesla-meta-microsoft-power-metallic-mines-lululemon-what-brokers-said-this-week-1086599.html
title: 'Tesla, Meta, Microsoft, Power Metallic Mines, Lululemon: What brokers said
  this week'
tags:
  - policy
---

Jefferies analysts lowered their price target on Lululemon Athletica Inc (NASDAQ:LULU) stock to $185 from $200, coinciding with the outgoing CEO Calvin McDonald's final day at the company.

Shares of Lululemon traded at about $174 on Friday, down almost 60% in the last 12 months.

30 Jan 2026

Apple Inc (NASDAQ:AAPL, XETRA:APC) delivered a strong start to its fiscal 2026, with robust iPhone sales and record device installations driving better-than-expected revenue and profit for its first quarter, according to analysts, though rising memory costs could temper future gains.

Apple reported total revenue of $143.8 billion for its first fiscal quarter, up 16% year-on-year and above Wall Street estimates of $138.4 billion. Earnings per share came in at $2.84, beating the Street's forecast of $2.68. iPhone revenue surged 23% to $85.3 billion, with China showing standout growth of 38%, fueled by record upgraders, according to analysts.

30 Jan 2026

Citi warned of growing risks in commodities markets, as copper prices surged this week despite what analysts see as weak fundamentals, while oil and gold markets reacted to heightened tension in the Middle East.

In a note first published on Thursday, Tom Mulqueen, Citi's head of metals research, said copper could rise as high as $15,000-$16,000/t in the coming weeks, driven by Chinese investor flows following precious metals momentum and dollar weakness.

30 Jan 2026

AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) licensing deal on Friday signals a plausible effort by the FTSE 100 group to grab a piece of a booming market for obesity treatments, analysts said, with still plenty to go far despite the market currently being dominated by rivals Novo Nordisk and Eli Lilly.

The pharmaceutical group agreed to pay China's CSPC Pharmaceuticals $1.2 billion upfront, with a further $3.5 billion in milestone payments, for rights to eight early-stage weight management and diabetes programmes, including a clinical-ready injectable drug expected...

[Read the original article](https://www.proactiveinvestors.com/companies/news/1086599/tesla-meta-microsoft-power-metallic-mines-lululemon-what-brokers-said-this-week-1086599.html)